Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jul;85(7):1616-1618.
doi: 10.1111/bcp.13950. Epub 2019 May 3.

Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome

Marco Previsdomini  1 , Elisa Graziano  1 , Laurent Decosterd  2 , Perrine Courlet  2 , Andreas Perren  1 , Alessandro Ceschi  3   4
Affiliations
Case Reports

Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome

Marco Previsdomini et al. Br J Clin Pharmacol. 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

There are no competing interests to declare.

Figures

Figure 1
Figure 1
Comparison between measured rosuvastatin plasma concentrations in the index patient and mean plasma values found in 10 healthy subjects after a single oral dose of 10 mg. Adapted from J. Gao et al.2
See this image and copyright information in PMC

References

    1. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine. 2005;84(6):377‐385. - PubMed
    1. Gao J, Zhong D, Duan X, Chen X. Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of rosuvastatin in human plasma: application to a pharmacokinetic study. J of Chromatog B Analyt Technol Biomed Life Sci. 2007;856(1–2):35‐40. - PubMed
    1. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs. 2004;4(2):117‐138. - PubMed
    1. Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol. 2003;58(10):669‐675. - PubMed
    1. Huang F, Marzin K, Koenen R, et al. Effect of steady‐state faldaprevir on pharmacokinetics of atorvastatin or rosuvastatin in healthy volunteers: a prospective open‐label, fixed‐sequence crossover study. Clin Pharmacol. 2017;57(10):1305‐1314. - PubMed

MeSH terms

Substances